SCHEMBL4490726

SCHEMBL4490726

Cc1[nH]c(C)c(-c2ccc(OCc3ccc(C(F)(F)F)cc3)nc2)c(=O)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.61
ADAMTS4 O75173 1/20 0.40
KDR P35968 1/20 0.38
TEK Q02763 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.38
PTPN1 P18031 1/20 0.38
PTGES O14684 3/20 0.36
GABRA5 P31644 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
DAO P14920 2/20 0.36
MAOB P27338 2/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
DGAT1 O75907 1/20 0.35
LIPE Q05469 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487955 0.91 SLC2A1 (0.66) SLC2A1ADAMTS4KDRMRGPRX4PTPN1
SCHEMBL4469233 0.88 SLC2A1 (0.52) SLC2A1PTGESGABRA5
SCHEMBL4468888 0.88 SLC2A1 (0.79) SLC2A1MRGPRX4HCAR2MAOB
SCHEMBL4476493 0.88 SLC2A1 (0.52) SLC2A1PTGES
SCHEMBL4476159 0.88 SLC2A1 (0.79) SLC2A1ADAMTS4KDRTEKMRGPRX4
SCHEMBL13754686 0.86 SLC2A1 (0.56) SLC2A1GABRA5
SCHEMBL4484452 0.83 SLC2A1 (0.53) SLC2A1PTPN1PTGES
SCHEMBL4480629 0.82 DAO (0.44) SLC2A1DAOMAOB
SCHEMBL4493447 0.82 SLC2A1 (0.52) SLC2A1PTGESHCAR2MAOBHDAC1
SCHEMBL4565033 0.81 SLC2A1 (0.43) SLC2A1MAOBDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885ADAMTS4 3505/4885KDR 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.